SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Not Allowed)
About
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Not Allowed) is a federal funding opportunity from National Institutes of Health. This forecasted grant opportunity (FOR-OD-26-006) is available nationwide for eligible applicants.
The SBIR/STTR Commercialization Readiness Pilot (CRP) Program is a federal funding initiative from the National Institutes of Health designed to accelerate the commercialization of innovative biomedical and health-related technologies developed by small businesses. This program supports Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awardees in moving their promising research discoveries closer to market readiness and commercialization. The CRP Program is particularly valuable for entrepreneurs and small business owners who have completed preliminary research phases and are ready to demonstrate the commercial viability of their innovations. By providing targeted support during this critical transition period, the program helps bridge the gap between research and commercial deployment. This opportunity is available to eligible applicants nationwide and represents a strategic investment in accelerating the path to commercialization for federally-funded research. Entrepreneurs developing medical devices, diagnostic tools, therapeutics, and other health-related innovations should consider applying. The program emphasizes moving viable technologies toward market introduction, helping small businesses refine their commercial strategies, validate market demand, and prepare for investment or licensing opportunities. For the most current information regarding funding amounts, specific eligibility requirements, and application timelines, applicants should consult the official NIH announcement.
Grant Details
Funding Range
Varies by cycle
Grant Type
Federal
Application Cycle
Check official NIH announcement for current cycle timing
Best For
Small businesses with prior SBIR/STTR funding ready to commercialize biomedical innovations
Frequently Asked Questions
Who is eligible for SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Not Allowed)?
Eligibility is typically limited to small businesses that have received prior SBIR or STTR funding from the National Institutes of Health and are ready to commercialize their research findings. The program specifically excludes parent projects involving clinical trials, as indicated in the program name. For detailed eligibility criteria, applicant size requirements, and specific qualification standards, consult the official NIH Funding Opportunity Announcement (FOR-OD-26-006) on grants.nih.gov.
How much funding does SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Not Allowed) provide?
Funding amounts for this program vary by funding cycle and the specific needs of the proposed commercialization project. For current information on available funding levels, award ranges, and budget limitations, applicants should review the official NIH funding opportunity announcement on grants.nih.gov.
How do I apply for SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Not Allowed)?
Applications are submitted through the official NIH grants application system. Applicants should visit grants.nih.gov and search for the specific funding opportunity (FOR-OD-26-006) to access the full announcement, application instructions, and submission portal. The application typically requires documentation of prior SBIR/STTR funding, a commercialization plan, market analysis, and detailed budget justification. Check the official announcement for current deadlines and specific submission requirements.
What can SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Not Allowed) funding be used for?
Funding is intended to support commercialization readiness activities that move research innovations toward market introduction. This typically includes market validation, proof-of-concept demonstrations, intellectual property protection, regulatory pathway planning, manufacturing feasibility studies, and commercialization strategy development. The program excludes clinical trial activities for parent projects. For specific allowable and unallowable use of funds, consult the detailed program guidelines on the NIH website.
Last updated: March 1, 2026